{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:41:32Z","timestamp":1792510892353,"version":"4.5.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Immunotherapy has shown limited success in acute myeloid leukemia (AML), indicating an incomplete understanding of the underlying immunoregulatory mechanisms. Here we identify an immune evasion mechanism present in 60% of AML cases, wherein primitive AML cells aberrantly express the lymphoid surface protein SLAMF6 (signaling lymphocyte activation molecule family member 6). Knockout of\n                    <jats:italic>SLAMF6<\/jats:italic>\n                    in AML cells enables T cell activation and highly efficient killing of leukemia cells in coculture systems, demonstrating that SLAMF6 protects AML cells from recognition and elimination by the immune system in a mode analogous to the programmed cell death protein\u2013ligand (PDL1\/PD1) axis. Targeting SLAMF6 with an antibody against the SLAMF6 dimerization site inhibits the SLAMF6\u2013SLAMF6 interaction and induces T cell activation and killing of AML cells both in vitro and in humanized in vivo models. In conclusion, we show that aberrant expression of SLAMF6 is a common and targetable immune escape mechanism that could pave the way for immunotherapy in AML.\n                  <\/jats:p>","DOI":"10.1038\/s43018-025-01054-6","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T09:04:34Z","timestamp":1759482274000},"page":"1821-1838","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Aberrant expression of SLAMF6 constitutes a targetable immune escape mechanism in acute myeloid leukemia"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8931-9565","authenticated-orcid":false,"given":"Carl","family":"Sand\u00e9n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6752-6507","authenticated-orcid":false,"given":"Niklas","family":"Landberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0789-6431","authenticated-orcid":false,"given":"Pablo","family":"Pe\u00f1a-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5393-2942","authenticated-orcid":false,"given":"Hanna","family":"Thorsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Daga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelia","family":"Puente-Moncada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Rodriguez-Zabala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"von Palffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Rissler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1782-4423","authenticated-orcid":false,"given":"Vladimir","family":"Lazarevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Juliusson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5105-1938","authenticated-orcid":false,"given":"Mats","family":"Ohlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Hyrenius-Wittsten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6533-0305","authenticated-orcid":false,"given":"Christina","family":"Orsmark-Pietras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8703-1173","authenticated-orcid":false,"given":"Henrik","family":"Lilljebj\u00f6rn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"\u00c5gerstam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3235-6154","authenticated-orcid":false,"given":"Thoas","family":"Fioretos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"key":"1054_CR1","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3324\/haematol.2022.280800","volume":"108","author":"P Stelmach","year":"2023","unstructured":"Stelmach, P. & Trumpp, A. Leukemic stem cells and therapy resistance in acute myeloid leukemia. Haematologica 108, 353\u2013366 (2023).","journal-title":"Haematologica"},{"key":"1054_CR2","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s12015-021-10308-6","volume":"18","author":"NA Long","year":"2022","unstructured":"Long, N. A., Golla, U., Sharma, A. & Claxton, D. F. Acute myeloid leukemia stem cells: origin, characteristics, and clinical implications. Stem Cell Rev. Rep. 18, 1211\u20131226 (2022).","journal-title":"Stem Cell Rev. Rep."},{"key":"1054_CR3","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1002\/cncr.33458","volume":"127","author":"K Sasaki","year":"2021","unstructured":"Sasaki, K. et al. De novo acute myeloid leukemia: a population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. Cancer 127, 2049\u20132061 (2021).","journal-title":"Cancer"},{"key":"1054_CR4","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1182\/blood.2019001728","volume":"134","author":"G Juliusson","year":"2019","unstructured":"Juliusson, G. et al. Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period. Blood 134, 1558\u20131561 (2019).","journal-title":"Blood"},{"key":"1054_CR5","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg8014","volume":"9","author":"F Manfredi","year":"2023","unstructured":"Manfredi, F. et al. Harnessing T cell exhaustion and trogocytosis to isolate patient-derived tumor-specific TCR. Sci. Adv. 9, eadg8014 (2023).","journal-title":"Sci. Adv."},{"key":"1054_CR6","doi-asserted-by":"publisher","unstructured":"Panoskaltsis, N., Reid, C. D. & Knight, S. C. Quantification and cytokine production of circulating lymphoid and myeloid cells in acute myelogenous leukaemia. Leukemia https:\/\/doi.org\/10.1038\/sj.leu.2402835 (2003).","DOI":"10.1038\/sj.leu.2402835"},{"key":"1054_CR7","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","volume":"176","author":"P van Galen","year":"2019","unstructured":"van Galen, P. et al. Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity. Cell 176, 1265\u20131281 e1224 (2019).","journal-title":"Cell"},{"key":"1054_CR8","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/cncr.31896","volume":"125","author":"P Williams","year":"2019","unstructured":"Williams, P. et al. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer 125, 1470\u20131481 (2019).","journal-title":"Cancer"},{"key":"1054_CR9","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1182\/blood-2011-11-394395","volume":"120","author":"J Greiner","year":"2012","unstructured":"Greiner, J. et al. Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia. Blood 120, 1282\u20131289 (2012).","journal-title":"Blood"},{"key":"1054_CR10","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/nature13387","volume":"512","author":"T Schumacher","year":"2014","unstructured":"Schumacher, T. et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 512, 324\u2013327 (2014).","journal-title":"Nature"},{"key":"1054_CR11","doi-asserted-by":"publisher","unstructured":"Vadakekolathu, J. et al. Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.aaz0463 (2020).","DOI":"10.1126\/scitranslmed.aaz0463"},{"key":"1054_CR12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1177\/00045632231184716","volume":"61","author":"E You","year":"2024","unstructured":"You, E. et al. Increased PD-1 expression of bone marrow T-cells in acute myeloid leukaemia patients after stem cell transplantation, and its association with overall survival. Ann. Clin. Biochem. 61, 79\u201389 (2024).","journal-title":"Ann. Clin. Biochem."},{"key":"1054_CR13","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1182\/blood.2023021680","volume":"144","author":"F Mazziotta","year":"2024","unstructured":"Mazziotta, F. et al. CD8+ T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia. Blood 144, 1168\u20131182 (2024).","journal-title":"Blood"},{"key":"1054_CR14","doi-asserted-by":"publisher","unstructured":"Knaus, H. A. et al. Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.120974 (2018).","DOI":"10.1172\/jci.insight.120974"},{"key":"1054_CR15","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/ijc.25791","volume":"129","author":"Z Shenghui","year":"2011","unstructured":"Shenghui, Z. et al. Elevated frequencies of CD4(+) CD25(+) CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia. Int. J. Cancer 129, 1373\u20131381 (2011).","journal-title":"Int. J. Cancer"},{"key":"1054_CR16","doi-asserted-by":"publisher","unstructured":"Rutella, S. et al. Immune dysfunction signatures predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia. J. Clin. Invest. https:\/\/doi.org\/10.1172\/JCI159579 (2022).","DOI":"10.1172\/JCI159579"},{"key":"1054_CR17","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1182\/blood.2020006158","volume":"136","author":"DA Sallman","year":"2020","unstructured":"Sallman, D. A. et al. TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype. Blood 136, 2812\u20132823 (2020).","journal-title":"Blood"},{"key":"1054_CR18","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1007\/s00262-010-0909-y","volume":"59","author":"C Berthon","year":"2010","unstructured":"Berthon, C. et al. In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors. Cancer Immunol. Immunother. 59, 1839\u20131849 (2010).","journal-title":"Cancer Immunol. Immunother."},{"key":"1054_CR19","doi-asserted-by":"publisher","first-page":"622","DOI":"10.4161\/cbt.7.5.5689","volume":"7","author":"X Chen","year":"2008","unstructured":"Chen, X. et al. Clinical significance of B7-H1 (PD-L1) expression in human acute leukemia. Cancer Biol. Ther. 7, 622\u2013627 (2008).","journal-title":"Cancer Biol. Ther."},{"key":"1054_CR20","doi-asserted-by":"publisher","first-page":"5708","DOI":"10.1158\/1078-0432.CCR-04-2672","volume":"11","author":"H Tamura","year":"2005","unstructured":"Tamura, H. et al. Expression of functional B7-H2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia. Clin. Cancer Res. 11, 5708\u20135717 (2005).","journal-title":"Clin. Cancer Res."},{"key":"1054_CR21","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/leu.2013.355","volume":"28","author":"H Yang","year":"2014","unstructured":"Yang, H. et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia 28, 1280\u20131288 (2014).","journal-title":"Leukemia"},{"key":"1054_CR22","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/(SICI)1521-4141(199801)28:01<90::AID-IMMU90>3.0.CO;2-5","volume":"28","author":"RT Costello","year":"1998","unstructured":"Costello, R. T. et al. Regulation of CD80\/B7-1 and CD86\/B7-2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition. Eur. J. Immunol. 28, 90\u2013103 (1998).","journal-title":"Eur. J. Immunol."},{"key":"1054_CR23","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.ccell.2020.08.019","volume":"38","author":"O Dufva","year":"2020","unstructured":"Dufva, O. et al. Immunogenomic landscape of hematological malignancies. Cancer Cell 38, 424\u2013428 (2020).","journal-title":"Cancer Cell"},{"key":"1054_CR24","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/S0301-472X(01)00768-8","volume":"30","author":"F Re","year":"2002","unstructured":"Re, F. et al. Expression of CD86 in acute myelogenous leukemia is a marker of dendritic\/monocytic lineage. Exp. Hematol. 30, 126\u2013134 (2002).","journal-title":"Exp. Hematol."},{"key":"1054_CR25","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s12185-016-2153-5","volume":"105","author":"MM Ismail","year":"2017","unstructured":"Ismail, M. M. & Abdulateef, N. A. B. Bone marrow T-cell percentage: A novel prognostic indicator in acute myeloid leukemia. Int. J. Hematol. 105, 453\u2013464 (2017).","journal-title":"Int. J. Hematol."},{"key":"1054_CR26","doi-asserted-by":"publisher","first-page":"14331","DOI":"10.1073\/pnas.1916206117","volume":"117","author":"AJ Lamble","year":"2020","unstructured":"Lamble, A. J. et al. Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia. Proc. Natl Acad. Sci. USA 117, 14331\u201314341 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1054_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26282-z","volume":"12","author":"HA Abbas","year":"2021","unstructured":"Abbas, H. A. et al. Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. Nat. Commun. 12, 6071 (2021).","journal-title":"Nat. Commun."},{"key":"1054_CR28","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-21-3594","volume":"28","author":"G Corradi","year":"2022","unstructured":"Corradi, G. et al. Release of IFNgamma by acute myeloid leukemia cells remodels bone marrow immune microenvironment by inducing regulatory T cells. Clin. Cancer Res. 28, 3141\u20133155 (2022).","journal-title":"Clin. Cancer Res."},{"key":"1054_CR29","first-page":"27","volume":"4","author":"A Lasry","year":"2023","unstructured":"Lasry, A. et al. An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia. Nat. Cancer 4, 27\u201342 (2023).","journal-title":"Nat. Cancer"},{"key":"1054_CR30","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","volume":"9","author":"N Daver","year":"2019","unstructured":"Daver, N. et al. Efficacy, safety, and biomarkers of response to Azacitidine and Nivolumab in relapsed\/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study. Cancer Discov. 9, 370\u2013383 (2019).","journal-title":"Cancer Discov."},{"key":"1054_CR31","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1056\/NEJMoa1601202","volume":"375","author":"MS Davids","year":"2016","unstructured":"Davids, M. S. et al. Ipilimumab for patients with relapse after allogeneic transplantation. N. Engl. J. Med. 375, 143\u2013153 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1054_CR32","doi-asserted-by":"crossref","unstructured":"Prebet, T. et al. A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia. Leuk. Lymphoma 63, 2180\u20132188 (2022).","DOI":"10.1080\/10428194.2022.2057484"},{"key":"1054_CR33","doi-asserted-by":"crossref","unstructured":"Zeidner, J. F. et al. Phase II trial of Pembrolizumab after high-dose Cytarabine in relapsed\/refractory acute myeloid leukemia. Blood Cancer Discov. 2, 616\u2013629 (2021).","DOI":"10.1158\/2643-3230.BCD-21-0070"},{"key":"1054_CR34","doi-asserted-by":"publisher","first-page":"18662","DOI":"10.1074\/jbc.M312313200","volume":"279","author":"PA Valdez","year":"2004","unstructured":"Valdez, P. A. et al. NTB-A, a new activating receptor in T cells that regulates autoimmune disease. The Journal of biological chemistry 279, 18662\u201318669 (2004).","journal-title":"The Journal of biological chemistry"},{"key":"1054_CR35","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1158\/2326-6066.CIR-17-0383","volume":"6","author":"G Eisenberg","year":"2018","unstructured":"Eisenberg, G. et al. Soluble SLAMF6 Receptor Induces Strong CD8(+) T-cell Effector Function and Improves Anti-Melanoma Activity In Vivo. Cancer Immunol Res 6, 127\u2013138 (2018).","journal-title":"Cancer Immunol Res"},{"key":"1054_CR36","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1158\/2326-6066.CIR-18-0664","volume":"7","author":"B Yigit","year":"2019","unstructured":"Yigit, B. et al. SLAMF6 as a regulator of exhausted CD8(+) T cells in cancer. Cancer Immunol. Res. 7, 1485\u20131496 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"1054_CR37","doi-asserted-by":"publisher","unstructured":"Hajaj, E. et al. SLAMF6 deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint. Elife https:\/\/doi.org\/10.7554\/eLife.52539 (2020).","DOI":"10.7554\/eLife.52539"},{"key":"1054_CR38","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1038\/sj.leu.2401903","volume":"14","author":"CT Jordan","year":"2000","unstructured":"Jordan, C. T. et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 14, 1777\u20131784 (2000).","journal-title":"Leukemia"},{"key":"1054_CR39","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1309\/AJCPG8XH7ZONAKXK","volume":"140","author":"ZI Chakhachiro","year":"2013","unstructured":"Chakhachiro, Z. I. et al. CD105 (endoglin) is highly overexpressed in a subset of cases of acute myeloid leukemias. Am. J. Clin. Pathol. 140, 370\u2013378 (2013).","journal-title":"Am. J. Clin. Pathol."},{"key":"1054_CR40","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.stem.2015.08.008","volume":"17","author":"M Iwasaki","year":"2015","unstructured":"Iwasaki, M., Liedtke, M., Gentles, A. J. & Cleary, M. L. CD93 marks a non-quiescent human leukemia stem cell population and is required for development of MLL-rearranged acute myeloid leukemia. Cell Stem Cell 17, 412\u2013421 (2015).","journal-title":"Cell Stem Cell"},{"key":"1054_CR41","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/s43018-020-0103-x","volume":"1","author":"H Zhang","year":"2020","unstructured":"Zhang, H. et al. Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia. Nat. Cancer 1, 826\u2013839 (2020).","journal-title":"Nat. Cancer"},{"key":"1054_CR42","doi-asserted-by":"publisher","first-page":"10786","DOI":"10.1073\/pnas.1422749112","volume":"112","author":"H Agerstam","year":"2015","unstructured":"Agerstam, H. et al. Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia. Proc. Natl Acad. Sci. USA 112, 10786\u201310791 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1054_CR43","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1182\/blood-2012-01-404699","volume":"120","author":"L Barreyro","year":"2012","unstructured":"Barreyro, L. et al. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood 120, 1290\u20131298 (2012).","journal-title":"Blood"},{"key":"1054_CR44","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1182\/blood-2018-12-889725","volume":"133","author":"D Sasca","year":"2019","unstructured":"Sasca, D. et al. NCAM1 (CD56) promotes leukemogenesis and confers drug resistance in AML. Blood 133, 2305\u20132319 (2019).","journal-title":"Blood"},{"key":"1054_CR45","unstructured":"Lilljebjorn, H. et al. The cellular state space of AML unveils novel NPM1 subtypes with distinct clinical outcomes and immune evasion properties. Nat. Commun. (in the press)."},{"key":"1054_CR46","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","volume":"175","author":"M Sade-Feldman","year":"2018","unstructured":"Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175, 998\u20131013 e1020 (2018).","journal-title":"Cell"},{"key":"1054_CR47","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.cell.2017.05.035","volume":"169","author":"C Zheng","year":"2017","unstructured":"Zheng, C. et al. Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing. Cell 169, 1342\u20131356 e1316 (2017).","journal-title":"Cell"},{"key":"1054_CR48","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.immuni.2006.06.020","volume":"25","author":"E Cao","year":"2006","unstructured":"Cao, E. et al. NTB-A receptor crystal structure: insights into homophilic interactions in the signaling lymphocytic activation molecule receptor family. Immunity 25, 559\u2013570 (2006).","journal-title":"Immunity"},{"key":"1054_CR49","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573\u20133587 e3529 (2021).","journal-title":"Cell"},{"key":"1054_CR50","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13045-023-01424-6","volume":"16","author":"RS Bhansali","year":"2023","unstructured":"Bhansali, R. S., Pratz, K. W. & Lai, C. Recent advances in targeted therapies in acute myeloid leukemia. J. Hematol. Oncol. 16, 29 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"1054_CR51","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.clim.2018.10.013","volume":"204","author":"B Yigit","year":"2019","unstructured":"Yigit, B., Wang, N., Herzog, R. W. & Terhorst, C. SLAMF6 in health and disease: implications for therapeutic targeting. Clin. Immunol. 204, 3\u201313 (2019).","journal-title":"Clin. Immunol."},{"key":"1054_CR52","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3892\/ol.2022.13203","volume":"23","author":"Q Meng","year":"2022","unstructured":"Meng, Q. et al. SLAMF6\/Ly108 promotes the development of hepatocellular carcinoma via facilitating macrophage M2 polarization. Oncol. Lett. 23, 83 (2022).","journal-title":"Oncol. Lett."},{"key":"1054_CR53","doi-asserted-by":"publisher","first-page":"e0218109","DOI":"10.1371\/journal.pone.0218109","volume":"14","author":"MA Dragovich","year":"2019","unstructured":"Dragovich, M. A. et al. SLAMF6 clustering is required to augment T cell activation. PLoS One 14, e0218109 (2019).","journal-title":"PLoS One"},{"key":"1054_CR54","doi-asserted-by":"publisher","unstructured":"Gartshteyn, Y. et al. SLAMF6 compartmentalization enhances T cell functions. Life Sci. Alliance https:\/\/doi.org\/10.26508\/lsa.202201533 (2023).","DOI":"10.26508\/lsa.202201533"},{"key":"1054_CR55","doi-asserted-by":"publisher","first-page":"5931","DOI":"10.4049\/jimmunol.174.10.5931","volume":"174","author":"D Howie","year":"2005","unstructured":"Howie, D. et al. Cutting edge: the SLAM family receptor Ly108 controls T cell and neutrophil functions. J. Immunol. 174, 5931\u20135935 (2005).","journal-title":"J. Immunol."},{"key":"1054_CR56","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.immuni.2012.05.016","volume":"36","author":"R Kageyama","year":"2012","unstructured":"Kageyama, R. et al. The receptor Ly108 functions as a SAP adaptor-dependent on-off switch for T cell help to B cells and NKT cell development. Immunity 36, 986\u20131002 (2012).","journal-title":"Immunity"},{"key":"1054_CR57","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41590-019-0334-0","volume":"20","author":"Y Lu","year":"2019","unstructured":"Lu, Y. et al. SLAM receptors foster iNKT cell development by reducing TCR signal strength after positive selection. Nat. Immunol. 20, 447\u2013457 (2019).","journal-title":"Nat. Immunol."},{"key":"1054_CR58","doi-asserted-by":"publisher","unstructured":"Rietdijk, S., Keszei, M., Castro, W., Terhorst, C. & Abadia-Molina, A. C. Characterization of ly108-H1 signaling reveals ly108-3 expression and additional strain-specific differences in lupus prone mice. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms24055024 (2023).","DOI":"10.3390\/ijms24055024"},{"key":"1054_CR59","doi-asserted-by":"publisher","first-page":"632","DOI":"10.4049\/jimmunol.1101429","volume":"188","author":"R Uzana","year":"2012","unstructured":"Uzana, R. et al. Trogocytosis is a gateway to characterize functional diversity in melanoma-specific CD8+ T cell clones. J. Immunol. 188, 632\u2013640 (2012).","journal-title":"J. Immunol."},{"key":"1054_CR60","doi-asserted-by":"publisher","first-page":"26346","DOI":"10.18632\/oncotarget.8378","volume":"7","author":"B Yigit","year":"2016","unstructured":"Yigit, B. et al. A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cells. Oncotarget 7, 26346\u201326360 (2016).","journal-title":"Oncotarget"},{"key":"1054_CR61","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.stem.2013.05.014","volume":"13","author":"H Oguro","year":"2013","unstructured":"Oguro, H., Ding, L. & Morrison, S. J. SLAM family markers resolve functionally distinct subpopulations of hematopoietic stem cells and multipotent progenitors. Cell Stem Cell 13, 102\u2013116 (2013).","journal-title":"Cell Stem Cell"},{"key":"1054_CR62","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1172\/JCI129204","volume":"130","author":"L Vago","year":"2020","unstructured":"Vago, L. & Gojo, I. Immune escape and immunotherapy of acute myeloid leukemia. J.\u00ffClin. Invest. 130, 1552\u20131564 (2020).","journal-title":"J.\u00ffClin. Invest."},{"key":"1054_CR63","doi-asserted-by":"crossref","unstructured":"Huang, Y. et al. Loss of CD28 expression associates with severe T-cell exhaustion in acute myeloid leukemia. Front. Immunol. 14, 1139517 (2023).","DOI":"10.3389\/fimmu.2023.1139517"},{"key":"1054_CR64","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/j.1365-2141.2007.06569.x","volume":"137","author":"W Korver","year":"2007","unstructured":"Korver, W. et al. The lymphoid cell surface receptor NTB-A: a novel monoclonal antibody target for leukaemia and lymphoma therapeutics. Br. J. Haematol. 137, 307\u2013318 (2007).","journal-title":"Br. J. Haematol."},{"key":"1054_CR65","doi-asserted-by":"publisher","unstructured":"Dohner, H. et al. Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel. Blood https:\/\/doi.org\/10.1182\/blood.2022016867 (2022).","DOI":"10.1182\/blood.2022016867"},{"key":"1054_CR66","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber, D. A. et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 140, 1200\u20131228 (2022).","journal-title":"Blood"},{"key":"1054_CR67","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury, J. D. et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms.Leukemia 36, 1703\u20131719 (2022).","journal-title":"Leukemia"},{"key":"1054_CR68","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411\u2013420 (2018).","journal-title":"Nat. Biotechnol."},{"key":"1054_CR69","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s13059-019-1874-1","volume":"20","author":"C Hafemeister","year":"2019","unstructured":"Hafemeister, C. & Satija, R. Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. Genome Biol. 20, 296 (2019).","journal-title":"Genome Biol."},{"key":"1054_CR70","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888\u20131902.e21 (2019).","journal-title":"Cell"},{"key":"1054_CR71","doi-asserted-by":"publisher","unstructured":"Becht, E. et al. Dimensionality reduction for visualizing single-cell data using UMAP. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/nbt.4314 (2018).","DOI":"10.1038\/nbt.4314"},{"key":"1054_CR72","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nature13302","volume":"509","author":"MS Kim","year":"2014","unstructured":"Kim, M. S. et al. A draft map of the human proteome. Nature 509, 575\u2013581 (2014).","journal-title":"Nature"},{"key":"1054_CR73","doi-asserted-by":"publisher","unstructured":"Uhlen, M. et al. A genome-wide transcriptomic analysis of protein-coding genes in human blood cells. Science https:\/\/doi.org\/10.1126\/science.aax9198 (2019).","DOI":"10.1126\/science.aax9198"},{"key":"1054_CR74","doi-asserted-by":"publisher","unstructured":"Karlsson, M. et al. A single-cell type transcriptomics map of human tissues. Sci. Adv. https:\/\/doi.org\/10.1126\/sciadv.abh2169 (2021).","DOI":"10.1126\/sciadv.abh2169"},{"key":"1054_CR75","doi-asserted-by":"publisher","first-page":"1260419","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhlen","year":"2015","unstructured":"Uhlen, M. et al. Proteomics. Tissue-based map of the human proteome. Science 347, 1260419 (2015).","journal-title":"Science"},{"key":"1054_CR76","unstructured":"Kassambara, A., Kosinski, M. & Biecek, P. survminer: Drawing Survival Curves using \u2018ggplot2\u2019. R package version 0.4.9 https:\/\/rpkgs.datanovia.com\/survminer\/index.html (2024)."},{"key":"1054_CR77","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059\u20132074 (2013).","DOI":"10.1056\/NEJMoa1301689"},{"key":"1054_CR78","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","volume":"40","author":"D Bottomly","year":"2022","unstructured":"Bottomly, D. et al. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell 40, 850\u2013864 e859 (2022).","journal-title":"Cancer Cell"},{"key":"1054_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-020-06888-1","volume":"21","author":"H Li","year":"2020","unstructured":"Li, H., Sharma, A., Ming, W., Sun, X. & Liu, H. A deconvolution method and its application in analyzing the cellular fractions in acute myeloid leukemia samples. BMC Genomics 21, 652 (2020).","journal-title":"BMC Genomics"},{"key":"1054_CR80","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"1054_CR81","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. Nat. Methods 14, 417\u2013419 (2017).","journal-title":"Nat. Methods"},{"key":"1054_CR82","unstructured":"Blighe, K., Rana, S. & Lewis, M. EnhancedVolcano: publication-ready volcano plots with enhanced colouring and labeling. GitHub https:\/\/github.com\/kevinblighe\/EnhancedVolcano (2018)."},{"key":"1054_CR83","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1054_CR84","doi-asserted-by":"publisher","unstructured":"Korotkevich, G. et al. Fast gene set enrichment analysis. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/060012 (2021).","DOI":"10.1101\/060012"},{"key":"1054_CR85","first-page":"100141","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu, T. et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (Camb). 2, 100141 (2021).","journal-title":"Innovation (Camb)."},{"key":"1054_CR86","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkad1025","volume":"52","author":"M Milacic","year":"2024","unstructured":"Milacic, M. et al. The Reactome Pathway Knowledgebase 2024. Nucleic Acids Res. 52, D672\u2013D678 (2024).","journal-title":"Nucleic Acids Res."},{"key":"1054_CR87","doi-asserted-by":"publisher","unstructured":"The Gene Ontology Consortium et al. The Gene Ontology knowledgebase in 2023. Genetics https:\/\/doi.org\/10.1093\/genetics\/iyad031 (2023).","DOI":"10.1093\/genetics\/iyad031"}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-01054-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-01054-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-01054-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T18:10:28Z","timestamp":1764180628000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-01054-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":87,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["1054"],"URL":"https:\/\/doi.org\/10.1038\/s43018-025-01054-6","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]},"assertion":[{"value":"19 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.S. and N.L. are cofounders with equity in Lead Biologics International. T.F. is a cofounder and board member with equity in Lead Biologics International. C.S., N.L. and T.F. are inventors on patent applications on therapeutic targeting of SLAMF6, including but not limited to the TNC-1 antibody (including patent families WO2021111005 and WO2024240896 owned by Lead Biologics International). The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}